Abstract
Induced pluripotent stem (iPS) cells are human somatic cells that have been reprogrammed to a pluripotent state. There are several hurdles to be overcome before iPS cells can be considered as a potential patient-specific cell therapy, and it will be crucial to characterize the developmental potential of human iPS cell lines. As a research tool, iPS-cell technology provides opportunities to study normal development and to understand reprogramming. iPS cells can have an immediate impact as models for human diseases, including cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A retinoid analogue, TTNPB, promotes clonal expansion of human pluripotent stem cells by upregulating CLDN2 and HoxA1
Communications Biology Open Access 16 February 2024
-
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Molecular Cancer Open Access 28 November 2023
-
Modelling in vitro gametogenesis using induced pluripotent stem cells: a review
Cell Regeneration Open Access 16 October 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006).
Aoi, T. et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 14 Feb 2008 (doi:10.1126/science.1154884)
Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 448, 313–317 (2007).
Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).
Yu, J. et al. Induced pluripotent stem cells from adult human somatic cells. Science 318, 1917–1920 (2007).
Park, I.-H. et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141–147 (2008).
Lowry, W. E. et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc. Natl Acad. Sci. USA 105, 2883–2888 (2008).
Blelloch, R. et al. Generation of induced pluripotent stem cells in the absence of drug selection. Cell Stem Cell 1, 245–247 (2007).
Takahashi, K., Okita, K., Nakagawa, M. & Yamanaka, S. Induction of pluripotent stem cells from fibroblast cultures. Nature Protoc. 2, 3081–3089 (2007).
Yamanaka, S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 1, 39–49 (2007).
Cibelli, J. Development: is therapeutic cloning dead? Science 318, 1879–1880 (2007).
Jaenisch, R. & Young, R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 132, 567–582 (2008).
Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).
Cowan, C. A., Atienza, J., Melton, D. A. & Eggan, K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 309, 1369–1373 (2005).
Do, J. T., Han, D. W. & Scholer, H. R. Reprogramming somatic gene activity by fusion with pluripotent cells. Stem Cell Rev. 2, 257–264 (2006).
Hochedlinger, K. & Jaenisch, R. Nuclear reprogramming and pluripotency. Nature 441, 1061–1067 (2006).
Murry, C. E. & Keller, G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132, 661–680 (2008).
Lerou, P. H. & Daley, G. Q. Therapeutic potential of embryonic stem cells. Blood Rev. 19, 321–331 (2005).
Wernig, M. et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448, 318–324 (2007).
Maherali, N. et al. Directly reprogrammed fibroblasts show epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1, 55–70 (2007).
Hanna, J. et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318, 1920–1923 (2007).
The International Stem Cell Initiative. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nature Biotech. 25, 803–816 (2007).
Gottweis, H. & Minger, S. iPS cells and the politics of promise. Nature Biotech. 26, 271–272 (2008).
Cyranoski, D. Five things to know before jumping on the iPS bandwagon. Nature 452, 406–408 (2008).
Nakagawa, M. et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nature Biotech. 26, 101–106 (2008).
Osafune, K. et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nature Biotech. 26, 313–315 (2008).
US Department of Health and Human Services. Guidance for human somatic cell therapy and gene therapy. Food and Drug Administration [online] (1998).
Segers, V. F. M. & Lee, R. T. Stem cell therapy for cardiac disease. Nature 451, 937–942 (2008).
Rajasekhar, V. K. & Begemann, M. Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 25, 2498–2510 (2007).
Spivakov, M. & Fisher, A. G. Epigenetic signatures of stem-cell identity. Nature Rev. Genetics 8, 263–271 (2007).
Holden, C. & Vogel, G. A seismic shift for stem cell research. Science 319, 560–563 (2008).
Walker, F. O. Huntington's disease. Lancet 369, 218–228 (2007).
Hanna, J. et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 133, 250–264 (2008).
National Cancer Institute. Cancer biomedical informatics grid. National Cancer Institute [online] (2008).
Blelloch, R. H. et al. Nuclear cloning of embryonal carcinoma cells. Proc. Natl Acad. Sci. USA 101, 13985–13990 (2004).
Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Rev. Genetics 8, 286–298 (2007).
Hochedlinger, K. et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 18, 1875–1885 (2004).
Huebert, D. J. Kamal, M., O'Donovan, A. & Bernstein, B. E. Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 40, 365–369 (2006).
Robertson, G. et al. Genome-wide profiling of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nature Methods 4, 651–657 (2007).
Shultz, L. D., Ishikawa, F. & Greiner, D. L. Humanized mice in translational biomedical research. Nature Rev. Immunol. 7, 118–130 (2007).
Dimos, J. T. et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 31 July 2008 (doi:10.1126/science.1158799)
Park, I. -H et al. Disease-specific induced pluripotent stem cells. Cell (in the press).
Kim, J. B. et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 454, 646–650 (2008).
Acknowledgements
The authors thank A. L. Wong and A. J. Hwa for helpful comments.
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Nishikawa, Si., Goldstein, R. & Nierras, C. The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol 9, 725–729 (2008). https://doi.org/10.1038/nrm2466
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrm2466
This article is cited by
-
A retinoid analogue, TTNPB, promotes clonal expansion of human pluripotent stem cells by upregulating CLDN2 and HoxA1
Communications Biology (2024)
-
Modelling in vitro gametogenesis using induced pluripotent stem cells: a review
Cell Regeneration (2023)
-
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Molecular Cancer (2023)
-
New Solutions for Old Problems: How Reproductive Tissue Engineering Has Been Revolutionizing Reproductive Medicine
Annals of Biomedical Engineering (2023)
-
Forthcoming complications in recovered COVID-19 patients with COPD and asthma; possible therapeutic opportunities
Cell Communication and Signaling (2022)